Jun 17, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Oxygen Biotherapeutics, Inc. Enrolls First Patient In Traumatic Brain Injury Clinical
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2043480" data-attributes="member: 124445"><p>Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. "This trial is of invaluable importance in improving the outcome of patients with severe TBI. We hope to finally prove that there is a safe and effective treatment for this devastating injury," said Chris Stern, company chairman and CEO...<a href="http://feedads.g.doubleclick.net/~a/mlCq0vDT526nZC7xUupyXfeytFo/0/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/mlCq0vDT526nZC7xUupyXfeytFo/0/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p><a href="http://feedads.g.doubleclick.net/~a/mlCq0vDT526nZC7xUupyXfeytFo/1/da" target="_blank"><img src="http://feedads.g.doubleclick.net/~a/mlCq0vDT526nZC7xUupyXfeytFo/1/di" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></a></p><p></p><p><img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/443E-fSZVFk" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/443E-fSZVFk/173090.php" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2043480, member: 124445"] Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. "This trial is of invaluable importance in improving the outcome of patients with severe TBI. We hope to finally prove that there is a safe and effective treatment for this devastating injury," said Chris Stern, company chairman and CEO...[URL="http://feedads.g.doubleclick.net/~a/mlCq0vDT526nZC7xUupyXfeytFo/0/da"][IMG]http://feedads.g.doubleclick.net/~a/mlCq0vDT526nZC7xUupyXfeytFo/0/di[/IMG][/URL] [URL="http://feedads.g.doubleclick.net/~a/mlCq0vDT526nZC7xUupyXfeytFo/1/da"][IMG]http://feedads.g.doubleclick.net/~a/mlCq0vDT526nZC7xUupyXfeytFo/1/di[/IMG][/URL] [IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/443E-fSZVFk[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/443E-fSZVFk/173090.php]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top